Francesca Policastro
Research Subjects
Francesca Policastro has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Alessandro Amaddeo
Department of Medical, Surgical and Health Sciences; Pediatric Clinic, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy, Trieste, Italy
2 shared publicationsGiorgia Silli
Department of Medical, Surgical and Health Sciences; Pediatric Clinic, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy, Trieste, Italy
2 shared publicationsLaura Badina
Department of Medical, Surgical and Health Sciences; Pediatric Clinic, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy, Trieste, Italy
2 shared publicationsMassimo Maschio
Department of Medical, Surgical and Health Sciences; Pediatric Clinic, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy, Trieste, Italy
2 shared publicationsRoberta Sartori
Department of Medical, Surgical and Health Sciences; Pediatric Clinic, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy, Trieste, Italy
2 shared publicationsRoberto Casalaz
Department of Medical, Surgical and Health Sciences; Pediatric Clinic, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy, Trieste, Italy
2 shared publications
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA6038
Intrapulmonary Percussive Ventilation in pediatric patients with acute respiratory failure
Intrapulmonary Percussive Ventilation (IPV) is a recently developed airway clearance technique, useful to mobilize secretions, improve ventilation in the obstructed areas of the lung, and enhance gas exchange. Evidence highlights the positive effects of IPV for children with atelectasis, neurological diseases, neuromuscular diseases, pulmonary complications, acute bronchiolitis, and CF and PCD patients. In current clinical practice, the respiratory physiotherapists of the Hospital IRCCS Burlo Garofolo of Trieste use the IPV in the Emergency Unit and in the PICU. In the last year, 13 patients referred to the Emergency Unit or the PICU with acute respiratory failure (9 females, 6 males; mean-age 8.09 sd ±5.26). These patients were all affected by neurological or neuromuscular diseases. All patients were started on steroid therapy at admission; on average, chest physiotherapy with IPV was initiated 2 days after admission. 77% of the patients also required cough assistance and suctioning. Parameters were set patient by patient and recorded each session. Preliminary results are showing a decreasing of the length of stay in the emergency wards for these patients, compared to the historical cohort of the hospital. Yet, reduction of the atelectasis, decreasing of the need of invasive/non-invasive ventilation/respiratory support, and improving of the vital parameters (SPO2, HR, RR) are emerging. Some of these patients started the IPV and the cough assistance as home-treatment and will be followed-up to verify the eventual reduction of respiratory exacerbations, needing hospital.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA6038
Intrapulmonary Percussive Ventilation in pediatric patients with acute respiratory failure
Intrapulmonary Percussive Ventilation (IPV) is a recently developed airway clearance technique, useful to mobilize secretions, improve ventilation in the obstructed areas of the lung, and enhance gas exchange. Evidence highlights the positive effects of IPV for children with atelectasis, neurological diseases, neuromuscular diseases, pulmonary complications, acute bronchiolitis, and CF and PCD patients. In current clinical practice, the respiratory physiotherapists of the Hospital IRCCS Burlo Garofolo of Trieste use the IPV in the Emergency Unit and in the PICU. In the last year, 13 patients referred to the Emergency Unit or the PICU with acute respiratory failure (9 females, 6 males; mean-age 8.09 sd ±5.26). These patients were all affected by neurological or neuromuscular diseases. All patients were started on steroid therapy at admission; on average, chest physiotherapy with IPV was initiated 2 days after admission. 77% of the patients also required cough assistance and suctioning. Parameters were set patient by patient and recorded each session. Preliminary results are showing a decreasing of the length of stay in the emergency wards for these patients, compared to the historical cohort of the hospital. Yet, reduction of the atelectasis, decreasing of the need of invasive/non-invasive ventilation/respiratory support, and improving of the vital parameters (SPO2, HR, RR) are emerging. Some of these patients started the IPV and the cough assistance as home-treatment and will be followed-up to verify the eventual reduction of respiratory exacerbations, needing hospital.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA3951
Assessing the Health Related Quality of Life for patients with Cystic Fibrosis in Italy
Recent literature has increasingly focused on the significance of psychosocial well-being in patients with Cystic Fibrosis (CF). Within the multidisciplinary team, it is essential to incorporate the assessment of Health Related Quality of Life (HRQoL). The Regional Center of Cystic Fibrosis of Hospital IRCCS Burlo Garofolo of Trieste recently evaluated the psychometric properties of the EuroQoL-5Dimensions (EQ-5D) questionnaire in a cohort of patients with CF. The study involved 84 patients (41 females and 43 males, mean age = 27.54, sd = 15.07). The EQ-5D questionnaire was administered to inpatients (5) and outpatients (79). The scale used in this study demonstrated excellent internal consistency (Cronbach’s Alpha = 0.76), and excellent test-retest (Spearman’s Rho value = 0.75). The convergent validity (Rho = 0.47) indicates that the CFQR and the EQ-5D are not redundant. These results demonstrated that the EQ-5D is an appropriate, quick tool for administration to patients with CF, and can effectively complete the assessment made with the CFQR. EQ-5D has been implemented in the standard assessment of CF patients to understand their HRQoL. Data about the EQ-5D from all the patients of the Regional Center are now being collected from the multidisciplinary team, for 12 months. This cross-sectional study aims to describe the quality of life of CF patients by considering mobility, self-care, usual activities, pain/discomfort and anxiety/depression dimensions. Primary results show interesting data about the internalizing disorders domain.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA3951
Assessing the Health Related Quality of Life for patients with Cystic Fibrosis in Italy
Recent literature has increasingly focused on the significance of psychosocial well-being in patients with Cystic Fibrosis (CF). Within the multidisciplinary team, it is essential to incorporate the assessment of Health Related Quality of Life (HRQoL). The Regional Center of Cystic Fibrosis of Hospital IRCCS Burlo Garofolo of Trieste recently evaluated the psychometric properties of the EuroQoL-5Dimensions (EQ-5D) questionnaire in a cohort of patients with CF. The study involved 84 patients (41 females and 43 males, mean age = 27.54, sd = 15.07). The EQ-5D questionnaire was administered to inpatients (5) and outpatients (79). The scale used in this study demonstrated excellent internal consistency (Cronbach’s Alpha = 0.76), and excellent test-retest (Spearman’s Rho value = 0.75). The convergent validity (Rho = 0.47) indicates that the CFQR and the EQ-5D are not redundant. These results demonstrated that the EQ-5D is an appropriate, quick tool for administration to patients with CF, and can effectively complete the assessment made with the CFQR. EQ-5D has been implemented in the standard assessment of CF patients to understand their HRQoL. Data about the EQ-5D from all the patients of the Regional Center are now being collected from the multidisciplinary team, for 12 months. This cross-sectional study aims to describe the quality of life of CF patients by considering mobility, self-care, usual activities, pain/discomfort and anxiety/depression dimensions. Primary results show interesting data about the internalizing disorders domain.
- Open Access
- 20 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 1061
Narrative Review of the Pathophysiology of Post-Infectious Bronchiolitis Obliterans
Post-Infectious Bronchiolitis Obliterans (PIBO) is a rare chronic obstructive lung disease characterized by irreversible airflow limitation due to inflammation, fibrosis, and obliteration of the small airways following severe lower respiratory tract infection. Adenovirus is the most frequently associated pathogen, followed by other viruses and atypical bacteria. PIBO pathogenesis appears to result from a complex interaction between severe epithelial injury, dysregulated immune response, persistent neutrophilic inflammation, abnormal tissue repair, and genetic susceptibility. Epithelial damage triggers the release of inflammatory cytokines and epithelial-derived alarmins, promoting chronic inflammation and airway remodeling through fibrosis and airway obliteration driven by activation of the TGF-β/CTGF pathway, epithelial–mesenchymal transition, macrophage–fibroblast interactions, and extracellular matrix deposition. Genetic factors affecting mucociliary clearance, innate immunity, and fibrotic pathways may further predispose certain individuals to abnormal repair and fibrosis consequently. Histologically, PIBO progresses from inflammatory bronchiolitis to fibroproliferative remodeling and constrictive bronchiolitis with luminal obliteration. Understanding these mechanisms supports a stage-based therapeutic approach targeting inflammation in early disease and fibrotic remodeling in advanced stages.
- 20 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 1061
Open AccessNarrative Review of the Pathophysiology of Post-Infectious Bronchiolitis Obliterans
Post-Infectious Bronchiolitis Obliterans (PIBO) is a rare chronic obstructive lung disease characterized by irreversible airflow limitation due to inflammation, fibrosis, and obliteration of the small airways following severe lower respiratory tract infection. Adenovirus is the most frequently associated pathogen, followed by other viruses and atypical bacteria. PIBO pathogenesis appears to result from a complex interaction between severe epithelial injury, dysregulated immune response, persistent neutrophilic inflammation, abnormal tissue repair, and genetic susceptibility. Epithelial damage triggers the release of inflammatory cytokines and epithelial-derived alarmins, promoting chronic inflammation and airway remodeling through fibrosis and airway obliteration driven by activation of the TGF-β/CTGF pathway, epithelial–mesenchymal transition, macrophage–fibroblast interactions, and extracellular matrix deposition. Genetic factors affecting mucociliary clearance, innate immunity, and fibrotic pathways may further predispose certain individuals to abnormal repair and fibrosis consequently. Histologically, PIBO progresses from inflammatory bronchiolitis to fibroproliferative remodeling and constrictive bronchiolitis with luminal obliteration. Understanding these mechanisms supports a stage-based therapeutic approach targeting inflammation in early disease and fibrotic remodeling in advanced stages.